Repatha
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Repatha (evolocumab; Amgen/Astellas) is a fully human monoclonal immunoglobulin G2 antibody that inhibits PCSK9. PCSK9 is a protease involved in the intracellular and extracellular regulation of low-density lipoprotein receptor (LDLR) expression. It binds to the LDLR and targets it for lysosomal degradation within the hepatocytes. PCSK9 is also known to increase the production of apolipoprotein B-containing lipoproteins. Repatha prevents circulating PCSK9 from binding to the epidermal growth factor-like repeat A domain, its target on the LDLR. This consequently inhibits LDLR degradation, allowing the LDLRs to be recycled to the cell surface, thereby increasing plasma clearance of LDL-C.
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Repatha : Dyslipidemia
LIST OF FIGURES
8 Figure 1: LDL-C lowering in pivotal trials of PCSK9 inhibitors Repatha and Praluent
13 Figure 2: Datamonitor Healthcare’s drug assessment summary of Repatha for dyslipidemia
14 Figure 3: Datamonitor Healthcare’s drug assessment summary of Repatha for dyslipidemia
17 Figure 4: Repatha sales for dyslipidemia across the US, Japan, and five major EU markets, by country, 2018–27
LIST OF TABLES
5 Table 1: Recent high-impact events for Repatha in dyslipidemia
6 Table 2: Repatha drug profile
7 Table 3: Approval history of Repatha for dyslipidemia in the US, Japan, and five major EU markets
8 Table 4: PCSK9 inhibitors, Repatha and Praluent, cardiovascular outcomes (hazard ratios vs placebo)
10 Table 5: Clinical trials for Repatha in dyslipidemia
12 Table 6: Repatha for dyslipidemia – SWOT analysis
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Bempedoic Acid Franchise 
Sign up to the